Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
A Carmel institutional pharmacy could move its growing drug repackaging operation to Noblesville’s Corporate Campus if city leaders sign off on $225,000 in tax breaks.
With a half-dozen new products lined up for approval within two years, the fight to win the growing $22 billion U.S. diabetes market is expected to intensify.
Drugmakers under investigation for bribery have stopped promoting products in China, and physicians in some hospitals no longer want to meet sales representatives. Eli Lilly is among the drugmakers in China facing allegations.
Indiana's Medical Licensing Board is considering delaying for one year a proposed new rule that would require physicians to conduct annual toxicology tests on some patients as part of a larger state effort to crack down on prescription drug abuse.
Dr. Segun Rasaki, 49, prescribed drugs like hydrocodone and methadone to people who didn’t need them, and submitted fraudulent insurance claims such as duplicate billings, according to court documents.
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
The trial of 2,100 patients, called Expedition III, will use new measures of cognitive function, such as the ability to do tasks like cooking or driving, or remembering words after a delay.
Lisle, Ill.-based Catamaran Corp. has committed to hiring 104 full-time, permanent employees next year and a total of 205 by 2015.
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
Eli Lilly and Co. Chairman and CEO John Lechleiter is back to full-time work after taking a leave in May to have surgery for a dilated aorta, the company announced Monday morning.
A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London Tuesday.
Lilly’s drug, if approved, may be a significant competitor to Novo Nordisk A/S’s Victoza, which generated $1.64 billion in 2012.
Drug companies like Eli Lilly and Co. can be sued for paying rivals to delay low-cost versions of popular medicines, the U.S. Supreme Court said in a decision that rewrites the rules governing the release of generic drugs.
Eli Lilly and Co. will pay Canadian drug developer Transition Therapeutics Inc. at least $7 million and up to as much as $247 million to take over the development of a potential diabetes treatment.
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
Starting July 1, pharmacists will be able to offer a much wider variety of immunizations to customers, in an effort from lawmakers to make health care more accessible.
The study results, which will be released Monday afternoon, are part of Indianapolis-based Lilly’s campaign to get Medicare to pay for use of its brain imaging agent Amyvid.
Eli Lilly claims recent decisions by Canadian courts invalidating 17 drug patents have made the country an outlier among major developed countries.
The drug, enzastaurin, was in the most advanced stage of testing and had been expected to generate $260 million in annual sales by 2018.
